These cells are likely to be enriched in tumor-specific T cell clones in the tumor microenvironment, but CD39– tumor-specific T cells have been also identified and shown to have a higher proliferation capacity upon re-challenge compared to the CD39+ T cells [178]. This evidence concerns the gene ENTPD1 and neoplasm.